Triacylglycerol in adipose tissue is the major energy storage form in mammals. An imbalance between energy intake and expenditure can result in excess triacylglycerol accumulation in this tissue, resulting in obesity 1 . In morbid obesity increased adipocyte number (hyperplasia) may occur through adipocyte differentiation of precursor cells present in adipose tissue 2 . However, obesity is largely attributed to adipocyte hypertrophy that occurs when triacylglycerol synthesis exceeds breakdown (lipolysis), resulting in elevated triacylglycerol storage 1, 3 . Indeed, unlike the triacylglycerol synthesis 4, 5 that occurs at high levels in other tissues, including in the liver for very low density lipoprotein production, lipolysis for the liberation of fatty acids that can then be used as an energy source by other tissues is unique to adipocytes 6 . Furthermore, lipolysis in adipocytes is tightly regulated by hormones that are secreted according to nutritional status. During fasting, lipolysis is stimulated by catecholamines that increase cyclic AMP (cAMP) concentrations, whereas, in the fed state, lipolysis is inhibited by insulin 1, 3 . Although regulation of lipolysis by these endocrine factors has been extensively studied, the local regulation of lipolysis in adipose tissue by autocrine and paracrine factors is not well understood.
We recently identified an adipocyte phospholipase A 2 (PLA 2 ) by microarray analysis that we named AdPLA 7 (also called PLA2G16, HRASLS3, HREV107, HREV107-3, MGC118754 or H-REV107-1). AdPLA belongs to a newly discovered group of intracellular calciumdependent PLA 2 s 7 . The enzymes in the PLA 2 superfamily catalyze hydrolysis of the sn-2 ester bond of phospholipids 8 . The PLA 2 enzymes function in remodeling of membrane phospholipids by acylation and deacylation cycles 8 . Additionally, because the sn-2 position of phospholipids is typically enriched in arachidonic acid and other unsaturated fatty acids, PLA 2 enzymes catalyze the initial rate-limiting step in the production of eicosanoids 9 . Eicosanoids, including prostaglandins, are potent local mediators of signal transduction and are known to modulate many physiological systems. These signaling molecules exert autocrine action, paracrine action or both through binding to specific G-coupled stimulatory (Ga s ) or inhibitory (Ga i ) receptors that can, in turn, modulate a host of effects, including lipolysis through regulation of cAMP levels 10 . Although their physiological importance is unclear, there are some reports that suggest prostaglandins may modulate adipocyte differentiation in vitro [11] [12] [13] [14] . In mature adipocytes, depending on the concentrations used, some prostaglandins have been reported to stimulate, inhibit or exert no effect on lipolysis 15, 16 . Regardless, because AdPLA is highly expressed only in adipose tissue, we hypothesized that it could have a key role in adipose-specific processes such as lipolysis through modulation of arachidonic acid metabolism and its provision for prostaglandin biosynthesis.
Here we show that AdPLA is the major PLA 2 enzyme in adipose tissue and that it regulates lipolysis in an autocrine and paracrine manner through PGE 2 . We report that ablation of AdPLA prevents obesity from high fat feeding or leptin deficiency by regulating lipolysis through the PGE 2 -EP3-cAMP pathway.
RESULTS

AdPLA is highly expressed primarily in adipose tissue
As we have shown previously 7 , the 1.3-kilobase AdPLA messenger RNA and the 18-kDa AdPLA protein are expressed in mice in large amounts only in white adipose tissue (WAT) and brown adipose tissue (BAT) depots (Fig. 1a) . AdPLA is found exclusively in adipocytes and not in the stromal vascular fraction of adipose tissue that contains preadipocytes (Fig. 1a) . In humans, similar to mice, ADPLA mRNA was undetectable by RT-PCR in skeletal muscle and barely detectable in liver but was abundantly expressed in WAT (Fig. 1a) . We measured expression of all currently known intracellular PLA 2 enzymes 7 . We detected AdPLA at approximately 1,000-100,000-fold higher levels (Fig. 1b) , indicating that AdPLA is the major PLA 2 in adipose tissue. We investigated AdPLA regulation in different nutritional and hormonal states. The AdPLA mRNA level in epididymal WAT was low in fasted mice but markedly rose (by eightfold) after feeding the mice a high-carbohydrate, fat-free diet (P o 0.01) (Fig. 1c) . AdPLA mRNA expression was also low in adipose tissue of streptozotocin-diabetic mice, but it was similarly increased, by approximately tenfold, after insulin administration (Fig. 1c) . We observed substantially higher AdPLA mRNA expression in WAT of genetically obese ob/ob mice that are hyperinsulinemic and have markedly higher adipose tissue triacylglycerol storage (Fig. 1c) and higher AdPLA protein expression in obese ob/ob and db/db mice than in lean wild-type mice in both the fasted and refed states (Fig. 1c) . AdPLA is therefore highly and specifically expressed in adipocytes and is upregulated by feeding and insulin, and in obesity.
AdPLA-null mice are resistant to diet-induced obesity To elucidate the physiological role of AdPLA, we used gene targeting to generate AdPLA-null mice ( Supplementary Fig. 1 online) that we compared with wild-type littermates on a mixed genetic background (C57BL/6J and 129 SVJ) as well as on a C57BL/6J background (genetic backgrounds of mice used in specific experiments are indicated in the Methods). Although total body weights did not differ at weaning, at 11 weeks of age, AdPLA-null mice fed a high-fat diet (HFD) began to gain weight at a slower rate than wild-type littermates (Fig. 1d) . This disparity in body weight was exacerbated as mice aged, such that by 64 weeks of age, AdPLA-null mice fed a HFD weighed only 39.1 ± 0.2 g (n ¼ 3) versus wild-type littermates who weighed 73.7 ± 0.3 g (n ¼ 3), P o 0.001. The decreased weight gain was also observed in AdPLA-null mice fed a standard chow diet (SD), albeit to a lesser extent (Fig. 1d) . Food intakes in AdPLA-null and wild-type mice were equivalent, despite the differences in body weights (0.09 grams per day per gram body weight, n ¼ 6).
The lower body weight of AdPLA-null mice was largely accounted for by a reduction in WAT weight (Fig. 2a) . Body composition analysis indicated that AdPLA-null mice had decreased triacylglycerol content (Supplementary 
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L iv e r R e n E p i I n g B A T S M S p le e n K id n e y L u n g H e a r t P a n c r e a s depots compared to wild-type littermates with a combined WAT depot weight that was 74% lower (Fig. 2a) . We observed the same pattern of lower body and fat pad weight in AdPLA-null mice fed a SD and in AdPLA-null mice on a C57BL/6J background (data not shown). By standard pathology analysis, AdPLA-null mice showed no evidence of any gross, microscopic or functional abnormalities, aside from reduced adiposity ( Supplementary Fig. 2 online and data not shown). However, as described in later sections, upon HFD feeding we detected enlarged livers in AdPLA-null mice with increased liver triacylglycerol content (Supplementary Table 1 ), although various liver enzyme levels were largely normal except for alanine aminotransferase ( Supplementary Fig. 2) . Moreover, blood cell profile and immunological parameters in serum and adipose tissue were not changed in these mice compared to wild-type mice ( Supplementary  Fig. 2) , and the weights of other organs were similar between the two groups (data not shown).
AdPLA-null mice have normal adipogenesis A decrease in adipose tissue mass can result from a reduction in adipocyte size, a reduction in adipocyte number due to impaired differentiation, or both. Evidence indicates that AdPLA deficiency did not significantly affect adipocyte differentiation (Fig. 2a,b) . mRNA expression of adipogenic transcription factors 17, 18 including CCAAT/ enhancer-binding protein-a (Cebpa) and peroxisome proliferatoractivated receptor-g (Pparg) as well as the preadipocyte marker preadipocyte factor-1 (Pref1, also known as Dlk1) were similar in wild-type and AdPLA-deficient WAT, as were late markers of adipocyte differentiation, including fatty acid synthase (Fasn), diglyceride acyltransferase-1 (Dgat1), and adipocyte fatty acid-binding protein (Fabp4, also known as aP2 and aFabp) (Fig. 2b) . The DNA content in the fat depots of AdPLA-null and wild-type mice also did not differ significantly (140.4 ± 22.6 mg versus 123.7 ± 14.6 mg DNA per fat pad, respectively, n ¼ 6, P ¼ 0.55). We used mouse embryonic fibroblasts (MEFs) from wild-type and AdPLA-null embryos as well as 3T3-L1 cells transfected with AdPLA or control vector. After undergoing differentiation to adipocytes in medium containing a high concentration of insulin, there were no differences between wild-type and AdPLA-null MEFs or between AdPLA-overexpressing and control 3T3-L1 cells with regards to rounded adipocyte morphology or oil red O staining (Fig. 2b) . mRNA expression of adipocyte markers such as Cebpa, Pparg, Fabp4 and Pref1 were also similar between wild-type and AdPLA-null MEFs, confirming the same degree of differentiation (Fig. 2b) . Histological analysis showed that epididymal WAT from AdPLAnull mice contained a significantly greater frequency (P o 0.05) of small adipocytes and a lower frequency of midsized and large adipocytes (P o 0.01; Fig. 2c ). We also found substantially decreased triacylglycerol content in adipose tissue of AdPLA-null mice (Fig. 2a) . AdPLA ablation therefore causes adipocyte hypotrophy owing to lower triacylglycerol accumulation and smaller adipocyte size rather than impaired adipocyte differentiation.
AdPLA ablation increases lipolysis in adipose tissue
To investigate whether the markedly decreased adiposity observed in AdPLA-null mice was the result of increased lipolysis, we measured in vivo triacylglycerol metabolism over a two-week period with a recently developed heavy-water labeling technique 19 . The fractional contribution of triacylglycerol-glycerol synthesis to adipose tissue triacylglycerol was significantly higher in AdPLA-null mice, reflecting a greater than twofold higher rate of replacement of preexisting triacylglycerol molecules with newly labeled triacylglycerol-glycerol, indicating increased triacylglycerol turnover (Fig. 3a) . In agreement, the net in vivo lipolytic rate, calculated from the absolute rate of new triacylglycerol synthesis and the change in adipose tissue mass, was also four-to sixfold higher per gram of adipose tissue in AdPLA-null mice compared to wild-type mice (Fig. 3b) . We measured [U-14 C]palmitate incorporation into triacylglycerol in adipose tissue explants and found similar incorporation in wild-type or AdPLA-null mice, indicating comparable WAT fatty acid esterification in these mice (Fig. 3c) . Therefore, we conclude that triacylglycerol hydrolysis, but not synthesis, is altered in WAT of AdPLA-null mice.
To further investigate the effect of AdPLA ablation on lipolysis, we compared basal and stimulated glycerol and fatty acid release from explants of WAT from AdPLA-null and wild-type mice. Under basal conditions, the rates of glycerol and fatty acid release were significantly higher in adipose tissue from AdPLA-null mice (Fig. 3d) . Furthermore, lipolysis was also higher in AdPLA-deficient adipose tissue when treated with isoproterenol, which stimulates lipolysis by increasing cAMP levels (Fig. 3d) . Notably, the molar ratio of free fatty acid (FFA) to glycerol released from WAT explants was lower in AdPLA-null mice (Fig. 3e) . Because of the heterogeneity of cell populations within WAT explants, we also examined the effect of AdPLA ablation on lipolysis in adipocytes differentiated from MEFs that were isolated from AdPLA-null embryos. Probably owing to the very high concentration of insulin in the medium, the basal rate of lipolysis was very low in these cells, and we could not detect differences in basal lipolysis between adipocytes differentiated from wild-type and AdPLA-null MEFs (Fig. 3f) . This finding is in agreement with the comparable lipid content in MEF-differentiated adipocytes (Fig. 2b) . However, isoproterenol-stimulated lipolysis, measured as free fatty acid release, was significantly higher in adipocytes differentiated from AdPLA-null MEFs (Fig. 3f) . These results clearly indicate that lack of AdPLA results in increased lipolysis in adipose tissue.
AdPLA-null mice have reduced adipose PGE 2 levels Phospholipase A activity in WAT was considerably reduced, by 82%, in AdPLA-null mice (from 3.71 pmol mg -1 min -1 in wild-type mice to only 0.66 pmol mg -1 min -1 ), whereas expression of other PLA 2 enzymes were unchanged (Fig. 4a) . This finding establishes AdPLA as the major PLA in adipose tissue. Given the inverse relationship between PLA activity and lipolysis in AdPLA-null mice, we hypothesized that AdPLA may function in adipose tissue to regulate lipolysis locally by generating arachidonic acid for the production of prostaglandins. We first measured the abundance of prostaglandins known to be found in adipose tissue in wild-type mice. PGE 2 was present in significantly larger amounts than any other prostaglandins, which were detected in amounts well below the effective concentrations required for binding to their cognate receptors 20 (Fig. 4b) . We next determined the expression of the receptors for these prostaglandins in adipose tissue and found that EP3 was more highly expressed than other receptors examined, including IP, DP and EP1 (all undetectable), as well as EP2 and EP4, which were present in much smaller amounts (Fig. 4b) . When we compared the expression of various prostaglandins in adipose tissue from AdPLA-null and wild-type mice (Fig. 4b) , we found that expression of PGF 2 a and 15-deoxy-D 12,14 -PGJ 2 , which have been reported to affect adipocyte differentiation in vitro 13, 21, 22 , was unchanged in AdPLA-deficient adipose tissue (Fig. 4b) . However, PGE 2 expression was reduced to 12% of wild-type expression in AdPLA-deficient adipose tissue (Fig. 4b) . PGI 2 amounts were also significantly reduced (Fig. 4b) . However, PGI 2 concentrations were well below those required for receptor activation, and IP was not detected in adipose tissue (Fig. 4b) . Because PGE 2 and EP3 were found in adipose tissue at the highest concentrations, and because PGE 2 levels were the most markedly affected of the prostaglandins in AdPLA-null adipose tissue, we postulated that decreased activation of EP3 by PGE 2 , may have been a major contributor to the observed effects. If AdPLA regulates the production and release of PGE 2 , which can bind Ga i -coupled EP3, then cAMP levels should be increased in adipose tissue of AdPLA-null mice. Indeed, we detected an approximate twofold increase in cAMP concentrations relative to wild-type mice (Fig. 4c) and found significantly higher phosphorylation of hormone-sensitive lipase (HSL) in the absence of a change in HSL or desnutrin (also called ATGL) protein expression (Fig. 4d) . Our results support the idea that AdPLA expression induced by feeding and insulin inhibits lipolysis by increasing PGE 2 levels, which, in turn, activates EP3 and thereby decreases cAMP levels. In this regard, addition of exogenous PGE 2 decreased lipolysis to wild-type levels in differentiated adipocytes derived from AdPLA-null MEFs (Fig. 4e) and in WAT explants (data not shown), as well as in isolated adipocytes from AdPLA-null mice (Fig. 4f) . The addition of PGE 2 also restored cAMP levels in adipocytes isolated from AdPLA-null mice (Fig. 4g) . Addition of L826266, an EP3 antagonist, prevented the antilipolytic effect of PGE 2 in adipocytes (Fig. 4h) , providing evidence that EP3 mediates the antilipolytic effect of PGE 2 .
AdPLA ablation prevents obesity in ob/ob mice To test whether AdPLA deficiency could prevent genetic obesity such as that caused by leptin deficiency, we introduced AdPLA deficiency into ob/ob mice to generate double-knockout mice. On a SD, doubleknockout mice gained substantially less weight than did ob/ob mice (Fig. 5a,b) . Noteworthy differences in body weights were apparent by as early as 6 weeks of age and became even more pronounced with age (Fig. 5b) . To our surprise, the differences were not attributable to a reduction in food consumption, as food intakes were, in fact, somewhat increased in double-knockout mice compared to ob/ob mice (Fig. 5b) . However, double-knockout mice showed reduced adiposity, with a marked reduction in the weight of WAT depots compared to ob/ob mice (Fig. 5c) . Other organ weights, except for the increased liver weight, were similar between the two groups of mice (data not shown). Carcass analysis showed that body and carcass weights of AdPLA-null and double-knockout mice at 40 weeks of age were less than those of either wild-type or ob/ob mice, whereas the percentage of water and lean tissue mass was increased (Fig. 5d) . Percentage lipid was reduced by 81% in AdPLA-null mice and 69% in double-knockout mice compared to wild-type and ob/ob mice, respectively, reflecting the substantially leaner phenotype in AdPLA deficiency.
We observed significantly higher lipolysis in double-knockout mice under both basal and stimulated conditions compared to ob/ob mice (Fig. 5e) that was accompanied by an 86% reduction in PGE 2 amounts (Fig. 5f ) and a fourfold increase in cAMP levels (Fig. 5g) . In ob/ob mice, PGE 2 concentrations were 2.6-fold higher compared to wild-type mice, possibly reflecting their higher AdPLA levels (Fig. 5f) . Notably, PGE 2 expression in double-knockout mice did not differ from that in AdPLA-null mice, indicating that AdPLA dominantly regulates PGE 2 levels in adipose tissue (Fig. 5f) . Taken together, these results indicate that AdPLA deficiency markedly influences PGE 2 and cAMP levels to modulate lipolysis and adiposity, even in genetic obesity caused by leptin deficiency. AdPLA ablation causes insulin resistance Changes in adiposity are often associated with alterations in glucose and insulin homeostasis. AdPLA-null mice fed a SD showed an attenuated response to insulin during an insulin tolerance test (ITT) but showed glucose tolerance similar to wild-type mice ( Supplementary Fig. 3 online) , probably owing to elevated insulin secretion (Supplementary Table 2 online). AdPLA-null mice fed a HFD had significantly impaired glucose clearance during a glucose tolerance test (GTT) and an impaired response to insulin during ITT compared to wild-type littermates (Fig. 6a) . In addition, we found that AdPLA ablation further impaired glycemic control in ob/ob mice on both a SD (data not shown) and a HFD, making double-knockout mice even more glucose and insulin intolerant than the already impaired ob/ob mice (Fig. 6b) . In agreement with our findings from the GTT and ITT, AdPLA-null mice fed a SD showed normal fasting glucose but elevated serum insulin, whereas HFD-fed mice had elevated fasting serum glucose and insulin compared to wild-type mice (Supplementary Table 2 ). Serum glucose and insulin levels were also elevated in double-knockout compared with ob/ob mice on either diet (Supplementary Table 2 ).
To discern the impact of AdPLA ablation on peripheral and hepatic insulin action, we performed a hyperinsulinemic-euglycemic clamp. The glucose infusion rate necessary to maintain euglycemia in AdPLA-null mice was 77% lower than in wild-type mice, indicating severely blunted insulin-stimulated glucose uptake and metabolism ( Fig. 6c and Supplementary Fig. 3 online) . Compared with wild-type mice, AdPLA-null mice showed a 50% decrease in whole-body glucose uptake (Fig. 6d ) and 44% and 65% decreases (P o 0.05) in glycolysis and glycogen synthesis, respectively (data not shown), indicating decreased glucose metabolism. In addition, we found that suppression of hepatic glucose production by insulin during the clamp was severely blunted in AdPLA-null mice (Fig. 6e) , indicating hepatic insulin resistance. We found no difference in gastrocnemius 2-deoxyglucose uptake between wild-type and AdPLA-null mice (Fig. 6f) . Notably, epididymal WAT 2-deoxyglucose uptake per gram was higher in AdPLA-null mice, although the substantial decrease in adipose tissue mass resulted in a 72% reduction in total insulin-stimulated glucose uptake by this tissue (Fig. 6g) , which may explain the lower net whole body glucose metabolism in these mice.
The livers of AdPLA-null mice were pale tan in color and enlarged with numerous, lipid-laden vacuoles in hepatocytes ( Supplementary  Fig. 3 ). Liver diacylglycerol concentrations, which have been associated with insulin resistance 23 , were also significantly increased in AdPLA-null mice compared with wild-type mice (3.05 ± 0.46 mg mg -1 tissue versus 1.47 ± 0.38 mg mg -1 tissue, respectively, P o 0.05).
Lipid staining with oil red O also showed higher intramyocellular triacylglycerol content in skeletal muscle, although we found no difference in skeletal muscle diacylglycerol content (data not shown) or insulin receptor substrate-1 (IRS-1) phosphorylation ( Supplementary Fig. 3) .
We found that circulating amounts of leptin and adiponectin were decreased in AdPLA-null mice on either a SD or a HFD (Supplementary Table 2 ). Relative mRNA expression of these adipokines in WAT from HFD-fed mice was also decreased (1.0 ± 0.30 versus 0.25 ± 0.07, P o 0.01 for leptin; 1.0 ± 0.26 versus 0.28 ± 0.05, P o 0.01 for adiponectin, in wild-type and AdPLA-null mice, respectively). Circulating amounts of adiponectin were lower in ob/ob mice compared to double-knockout mice (Supplementary Table 2 ). Adiponectin has been shown to increase fatty acid oxidation in skeletal muscle 24 . We found decreased phosphorylation of AMP-activated protein kinase Fig. 3 ).
Despite increased lipolysis in AdPLA-null mice, serum nonesterified fatty acid (NEFA) levels were not higher but lower on both a SD and a HFD (Supplementary Table 2 ). Serum triglycerides were also lower in AdPLA-null and double-knockout mice, despite pronounced steatosis and hepatic insulin resistance (Supplementary Table 1 ). We found increased triacylglycerol clearance in mice upon oral feeding of lipids but no difference in serum triacylglycerol when we first injected the pharmacologic agent WR1339, which inhibits lipoprotein removal from the circulation ( Supplementary Fig. 4 online) . Lipoprotein lipase expression was twofold higher in livers from AdPLA-null mice ( Supplementary Fig. 4 ). Taken together, the results show that fatty acid uptake by the liver seems to be higher in AdPLA-null mice.
AdPLA ablation raises energy expenditure and fat oxidation Total oxygen consumption was higher in AdPLA-null and doubleknockout mice compared with wild-type and ob/ob mice, respectively (Fig. 6h) , and these differences were not attributable to changes in ambulatory activity (data not shown). Thus, we next examined BAT but found no significant difference in the morphology or weight of interscapular BAT, nor did we find any change in mRNA levels of genes involved in thermogenesis in BAT when mice were housed at 4 1C (data not shown). In WAT from AdPLA-null mice, however, we detected a 5.5-fold upregulation in mRNA levels of uncoupling protein-1 (Ucp1), as well as upregulation of other genes involved in oxidative metabolism, including 3.2-fold and fivefold increases in expression in mRNA levels of peroxisome proliferator-activated receptor-d (Ppard), and deiodinase-2 (Dio2), respectively (Fig. 6i) . We determined the production of 14 CO 2 from [U- 14 C]palmitate and found that fatty acid oxidation was increased by 37% in isolated adipocytes from AdPLA-null mice compared to wild-type mice (Fig. 6j) . Fatty acid oxidation was significantly lower in adipocytes from ob/ob mice than in those from wild-type mice but was restored to wild-type levels in double-knockout mice. We observed a decrease in the molar ratio of FFA to glycerol released from WAT explant studies of AdPLA-null mice compared to wild-type mice (Fig. 3e) . This change in the molar ratio of fatty acid to glycerol in AdPLA-null mice indicates increased use of FFA within adipocytes and supports our finding of increased fatty acid oxidation in adipose tissue. These findings help to explain not only increased energy expenditure but also decreased NEFA in the circulation, despite higher lipolysis in AdPLA-null mice.
DISCUSSION
AdPLA is highly expressed only in adipose tissue, where lipolysis is a major function. We postulated that, because PLA 2 enzymes catalyze the initial rate-limiting step in prostaglandin synthesis 9 , AdPLA may regulate lipolysis locally by controlling the provision of arachidonic acid for the production of prostaglandins. As AdPLA is induced by feeding and insulin, as well as in the ob/ob and db/db models of obesity, we predicted that AdPLA probably has an inhibitory role in lipolysis. Indeed, we found that AdPLA has a major role in modulating adipose tissue lipolysis by regulating PGE 2 abundance. As a result, ablation of AdPLA in mice prevented obesity induced by feeding on a HFD or by leptin deficiency.
The local regulation of lipolysis in adipose tissue by autocrine and paracrine factors such as PGE 2 has not been studied extensively compared to the regulation of this process by endocrine factors such as catecholamines and insulin 25 . We found that AdPLA is expressed in adipocytes at a much higher level than any other known PLA 2 enzymes, and total phospholipase A activity was greatly reduced in adipose tissue of AdPLA-null mice whereas expression of other known PLA 2 enzymes remained unchanged, revealing that AdPLA is the major PLA 2 enzyme in this tissue and may provide arachidonic acid for prostaglandin synthesis. Among the prostaglandins that have previously been detected in adipose tissue, we found that PGE 2 is present at levels one to two orders of magnitude higher than those of other prostaglandins. Furthermore, PGE 2 levels are markedly decreased in AdPLA-null and double-knockout mice, providing evidence for a key role for AdPLA in regulating PGE 2 synthesis. We found that the Ga i coupled receptor, EP3, which inhibits adenylyl cyclase and therefore negatively regulates cAMP levels, was predominant in adipose tissue. We also found that a specific inhibitor of EP3 prevented the antilipolytic effect of PGE 2 . These findings suggest that PGE 2 suppresses lipolysis by decreasing cAMP levels through EP3 activation during feeding when AdPLA is strongly induced by insulin. Indeed, we found that cAMP levels were elevated in WAT of AdPLA-null and double-knockout mice, and PGE 2 treatment restored cAMP levels in AdPLA-null adipocytes to wild-type levels. In AdPLA-null WAT, HSL phosphorylation was increased, whereas total amounts of HSL and desnutrin were unchanged, suggesting that phosphorylation of HSL through cAMP-mediated activation of protein kinase A is probably a key mediator of increased lipolysis in these mice. In vivo, lipolysis was markedly higher per gram of adipose tissue in AdPLA-null mice compared to wild-type mice. Furthermore, both basal and isoproterenol-stimulated lipolysis were increased in explants of AdPLA-deficient adipose tissue and in adipocytes isolated from AdPLA-null mice, and stimulated lipolysis was higher in adipocytes differentiated from AdPLA-null MEFs. Exogenous PGE 2 rescued lipolytic rates in AdPLA-deficient adipocytes in all three model systems, showing AdPLA regulation of lipolysis in adipocytes via PGE 2 production. The cyclooxygenase inhibitors NS-398 (ref. 26 ) and indomethacin 27 have been shown to enhance basal and stimulated lipolysis, respectively, in adipose tissue, consistent with our present findings that AdPLA has a major part in regulating lipolysis through production of PGE 2 . Furthermore, we show that an EP3 inhibitor prevents the antilipolytic effects of PGE 2 , which is consistent with our proposed model of lipolysis regulation by AdPLA through PGE 2 signaling. Owing to increased phosphorylation of HSL and unsuppressed lipolysis, AdPLA-null mice have markedly decreased triacylglycerol content in adipose tissue. This indicates that suppression of lipolysis by the local PGE 2 produced by adipocytes is crucial in regulating adipocyte lipolysis and shows a role for the AdPLA-PGE 2 -EP3-cAMP signaling pathway in development of excess adipose tissue mass, triacylglycerol storage and obesity. In support of this, PGE 2 abundance was found to be higher in adipose tissue of obese human subjects compared to normal weight controls 28 . Overall, the present study shows that AdPLA has a crucial regulatory role in the adipocyte dominant function of lipolysis through PGE 2 in an autocrine manner, a paracrine manner or both.
Fatty acids such as arachidonic acid that are released by the action of PLA 2 enzymes have been shown to either stimulate or inhibit adipocyte differentiation [29] [30] [31] . Similarly, selective cyclooxygenase-2 inhibitors 12, 14 or prostaglandins themselves 11, 13, 21, 22 were reported to induce or inhibit adipogenesis. PGF 2a , via its FP receptor, and 15-deoxy-D 12,14 -PGJ 2 , which is a ligand for PPAR-g, have been reported to affect in vitro adipocyte differentiation 13, 21 . PGD 2 may generate 15-deoxy-D 12,14 -PGJ 2 and PGI 2 and, through its IP receptor, may also affect adipocyte differentiation in vitro 11, 22 . However we have found that, unlike PGE 2 , these prostaglandins are not detected at high enough concentrations in adipose tissue to effectively bind their receptors 20 , which were also barely detectable in adipose tissue. Therefore, prostaglandins other than PGE 2 probably do not have a substantial role in modulating adipocyte processes, including differentiation. In our study, PGE 2 was the most abundant prostaglandin found in adipose tissue. However, our results clearly show that adipocyte differentiation, either in vitro or in vivo, was not affected by AdPLA.
The increased cAMP concentrations in WAT of AdPLA-null and AdPLA and leptin double-knockout mice resulted in increased lipolysis and, consequently, decreased adipocyte size with lower triacylglycerol content, despite similar food intakes. Although increased lipolysis in AdPLA-null mice resulted in ectopic triacylglycerol accumulation in the liver and skeletal muscle, this effect could not fully account for the loss of triacylglycerol from adipose tissue. Indeed, oxygen consumption was increased in AdPLA-null and double-knockout mice. Although we did not detect any changes in BAT, to our surprise, Ucp1, Dio2 and Ppard mRNA expression in WAT of AdPLA-null mice was substantially increased, suggesting higher oxidation and thermogenesis in WAT. Ectopic expression of Ucp1 in WAT has been reported to cause resistance to diet-induced obesity with increased fatty acid oxidation in adipocytes 32 . Consistent with this, we found significantly increased fatty acid oxidation in adipocytes from AdPLA-null and double-knockout mice compared with wild-type and ob/ob mice, respectively, indicating that, at least in part, increased fatty acid utilization within adipocytes contributed to the increased energy expenditure.
AdPLA-null and double-knockout mice are extremely lean but insulin resistant. Results from hyperinsulinemic-euglycemic clamping studies indicate that insulin resistance in AdPLA-null mice is due to hepatic insulin resistance as well as reduced peripheral glucose metabolism. Notably, there was no difference in insulin-stimulated skeletal muscle glucose uptake between wild-type and AdPLA-null mice, but total insulin-stimulated glucose-uptake was lower in WAT as a result of the marked decrease in the mass of this tissue. It is noteworthy that, despite severe insulin resistance and increased lipolysis in AdPLA-null mice, serum NEFA concentrations were lower in these mice. The molar ratio of FFA to glycerol release from adipose tissue was considerably lower in AdPLA-null mice, suggesting increased utilization of fatty acids within adipose tissue. Consistent with this finding, we observed increased fatty acid oxidation in adipose tissue. Ectopic storage of triacylglycerol in liver and skeletal muscle suggests that removal of FFA from the circulation by these tissues may potentially have been increased and therefore may also have contributed to decreased serum NEFA abundance. However, it is most likely that even with the higher rate of lipolysis, the markedly decreased adipose tissue mass in AdPLA-null mice resulted, overall, in lower net FFA liberation. Indeed, other mouse models with increased lipolysis and decreased adipose tissue mass also reported unchanged or reduced serum NEFA [33] [34] [35] [36] .
AdPLA expression in humans is also adipose specific (Supplementary Fig. 5 online) . Currently, little is known regarding the pathological phenotype of individuals lacking AdPLA. A database search for single-nucleotide polymorphisms (SNPs) in the PLA2G16 gene in humans identified one SNP within the coding region resulting in a Ser48Ala substitution. An additional 230 SNPs have also been detected within noncoding regions of the PLA2G16 gene. It is not known whether these result in altered protein function or abundance, and clinical associations for these SNPs have not been reported, most likely because our study is to our knowledge the first to characterize the physiological role of AdPLA. Many questions remain regarding the effect of partial or total PLA2G16 gene ablation in humans, and further research in this area will yield advances in understanding the pathology of human obesity as well as of type 2 diabetes.
METHODS
Cell culture. We isolated, maintained and differentiated MEFs and 3T3-L1 cells as previously described 37 .
RNA analysis. We subjected total RNA isolated with Trizol reagent (Invitrogen) to northern blotting (Amersham) or to quantitative RT-PCR or RT-PCR. We prevalidated primers used with the ABI PRISM 7700 sequence fast detection system (PE Applied Biosystems) for efficiency of amplification that was reported to be the same for all and essentially 100% by Applied Biosystems.
Western blotting. We separated proteins by 12% SDS-PAGE, transferred the proteins to nitrocellulose and probed the membrane with primary antibodies against AdPLA or desnutrin (Genemed Synthesis), IRS-1, phospho-IRS-1 (Ser307), phospho-AMPK-a (Thr172), AMPK-a, glyceraldehyde 3-phosphate dehydrogenase (Gapdh) or b-actin (Santa Cruz Biotechnology), HSL (Cell Signaling), or phosphoserine (Calbiochem).
Lipolysis. We performed lipolysis studies in adipocytes isolated as previously described 38 from gonadal WAT, in explants from freshly removed epididymal fat pads (B20 mg) and in MEFs differentiated to adipocytes. We incubated samples in Krebs-Ringer buffer (12 mM HEPES, 121 NaCl, 4.9 mM KCl, 1.2 mM MgSO 4 and 0.33 mM CaCl 2 ) with 3.5% fatty acid-free BSA and 0.1% glucose (KRB), with or without 200 nM isoproterenol (Sigma), PGE 2 (Cayman), adenosine deaminase (Calbiochem), 0.5 mM Triacsin C (Biomol) or L826266 (Merck Frosst Canada) and measured glycerol (Sigma) and fatty acid (Wako) content. We determined prostaglandin abundance by competitive enzyme immunoassay (R&D) after solid-phase extraction by C18 cartridges (Cayman), and we determined cAMP levels by competitive immunoassay (R&D).
Mouse maintenance. All studies received approval from the University of California at Berkeley Animal Care and Use Committee. We used mice on a pure C57BL/6J background, after backcrossing for ten generations, for studies of lipolysis, energy expenditure, hyperinsulinemic-euglycemic clamping, fatty acid oxidation, triacylglycerol clearance and for all studies on doubleknockout mice. In all other experiments, we compared AdPLA-null and wild-type littermates on a mixed genetic background (C57BL/6J and 129 SVJ), but we also confirmed the results in a C57BL/6J background. We provided either a SD or a HFD (45% of kcal from fat, 35% of kcal from carbohydrate and 20% of kcal from protein, Research Diets) ad libitum. To generate ob/ob mice deficient in AdPLA, we bred C57BL/6J mice heterozygous for the ob mutation (Jackson Laboratory) with AdPLA-null mice on a C57BL/ 6J background, resulting in heterozygotes that we interbred to produce doubleknockout mice.
Carcass and tissue analysis. We homogenized frozen, eviscerated carcasses from 40-week-old mice fed a HFD in water, dried the homogenates to a constant weight and estimated the lipid content by a previously described method 39 . We extracted tissue neutral lipids by a previously described method 40 , isolated triacylglycerol and diacylglycerol by thin-layer chromatography and quantified lipids with Infinity reagent (Thermo Trace) after sonification in 1% Triton X-100.
Glucose and insulin tolerance tests. For the GTT, we injected mice intraperitoneally with D-glucose (wild-type or knockout, 2 mg per g body weight; double-knockout or ob/ob mice, 0.625 mg per g body weight) after an overnight fast and monitored the tail blood glucose levels. For ITT, we injected mice with insulin (humulin, Eli Lilly) at a level of 0.5 mU per g body weight (wild-type and knockout mice on a SD), 0.75 mU per g body weight (wild-type and knockout mice fed a HFD) or 1.75 mU per g body weight (ob/ob and double-knockout mice) after a 5-h fast.
Hyperinsulenemic-euglycemic clamp. We implanted jugular venous catheters 7 d before the study. After an overnight fast, we infused [3-3 H]glucose (Perkin-Elmer) at a rate of 0.05 mCi min -1 for 2 h to assess basal glucose turnover, followed by the hyperinsulinemic-euglycemic clamp for 140 min with a primed and continuous infusion of human insulin (300 pmol kg -1 prime (43 mU kg -1 )) over 3 min followed by a 42 pmol kg -1 min -1 (6 mU kg -1 min -1 ) infusion (Novo Nordisk), a continuous infusion of H]glucose (0.1 mCi min -1 ) and a variable infusion of 20% dextrose to maintain euglycemia (B100-120 mg dl -1 ). We obtained plasma samples from the tail and measured tissue-specific glucose uptake after injection of a bolus of 10 mCi of 2-deoxy-D-[1-14 C]glucose (Perkin Elmer) at 85 min 41 . We analyzed our results as previously described 42 .
Histological analysis. We embedded tissues in paraffin and stained 6-mm-thick sections with H&E and determined adipocyte cell size with Image J software (US National Institutes of Health), measuring at least 300 cells from each sample.
Phospholipase A activity. We assayed supernatants of WAT for PLA activity by monitoring the liberation of [ 14 C]palmitate from 1,2-di[1-14 C]palmitoyl-snglycero-3-phosphocholine as previously described 43 .
Indirect calorimetry and body temperature. We measured oxygen consumption (VO 2 ) using the Oxymax system (Columbus Instruments).
2 H 2 O Labeling and gas chromatography-mass spectrometry analysis. We extracted lipids from gonadal fat pads of mice administered 2 H 2 O in drinking water for a 2-week period, trans-esterified the lipid phase by incubation with 3 N methanolic HCl and separated glycerol from fatty acid-methyl esters with the Folch technique 40 . We lyophilized and derivatized the aqueous phase containing free glycerol to glycerol triacetate by incubation with acetic anhydride-pyridine (2:1). We used a model 6890 gas chromatographer with a 5973 mass spectrometer (Agilent Technologies), fitted with a DB-225 fused silica column (J&W). We analyzed glycerol-triacetate under chemical ionization conditions by selected ion monitoring of mass-to-charge ratios (m/z) of 159-161 (representing M 0 -M 2 ) and fatty acid-methyl esters as described elsewhere 19 .
We measured fractional triacylglycerol-glycerol synthesis as previously described 19, 44 , with the following equation (see refs. 19,44 for details):
We estimated net lipolysis from f triacylglycerol synthesis and adipose mass as follows:
½f triacylglycerol Âðadipose mass = labeling timeÞ À ðDadipose mass=labeling timeÞ=fat pad mass
We excluded values with net lipolysis equivalent to zero from analysis.
Fatty acid oxidation. We determined fatty acid oxidation in isolated adipocytes as previously described 45 .
Statistical analyses. We assessed the results by Student's t-test to compare two groups or by one-way analysis of variance with Dunnett's post-hoc test for multiple comparisons and expressed them as means ± s.e.m. We analyzed adipocyte size distribution by the Wilcoxon signed rank Test.
Accession codes. Pla2g16 is located on chromosome 19 in the mouse genome. Reference sequence identifiers for mouse Pla2g16 in Entrez Gene are as follows: gene ID, 225845; gene, NC_000085.5; protein, NP_644675; mRNA, NM_139269.
Note: Supplementary information is available on the Nature Medicine website. 
